434 related articles for article (PubMed ID: 27883945)
1. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).
Almeida A; Fenaux P; List AF; Raza A; Platzbecker U; Santini V
Leuk Res; 2017 Jan; 52():50-57. PubMed ID: 27883945
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
3. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
4. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
List AF; Baker AF; Green S; Bellamy W
Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
[TBL] [Abstract][Full Text] [Related]
7. [Treatment for low-risk myelodysplastic syndromes].
Morita Y
Rinsho Ketsueki; 2018; 59(10):2050-2057. PubMed ID: 30305508
[TBL] [Abstract][Full Text] [Related]
8. Novel therapies in low- and high-risk myelodysplastic syndrome.
Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
[No Abstract] [Full Text] [Related]
9. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
[TBL] [Abstract][Full Text] [Related]
10. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.
Mies A; Platzbecker U
Semin Hematol; 2017 Jul; 54(3):141-146. PubMed ID: 28958287
[TBL] [Abstract][Full Text] [Related]
11. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
12. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
Molica M; Rossi M
Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
Komrokji RS; List AF
Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
List A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
[TBL] [Abstract][Full Text] [Related]
15. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Ma X; Steensma DP; Scott BL; Kiselev P; Sugrue MM; Swern AS
BMJ Open; 2018 Jul; 8(7):e019955. PubMed ID: 30037860
[TBL] [Abstract][Full Text] [Related]
16. Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
Castelli R; Schiavon R; Rossi V; Deliliers GL
Med Oncol; 2018 Apr; 35(5):76. PubMed ID: 29675620
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
Giagounidis AA
Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
[TBL] [Abstract][Full Text] [Related]
18. Treatment of MDS: something old, something new, something borrowed..
Sekeres MA
Hematology Am Soc Hematol Educ Program; 2009; ():656-63. PubMed ID: 20008251
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).
Jonasova A; Neuwirtova R; Polackova H; Siskova M; Stopka T; Cmunt E; Belickova M; Moudra A; Minarik L; Fuchs O; Michalova K; Zemanova Z
Leuk Res; 2018 Jun; 69():12-17. PubMed ID: 29614393
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of lower risk myelodysplastic syndromes].
Park S
Bull Cancer; 2023 Nov; 110(11):1156-1161. PubMed ID: 37500385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
